The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects
BDR Pharmaceuticals has launched BDENZA in 160mg strength aiding the convenience of prostate cancer patients. The medicine was previously available in 40mg and 80mg strength for which patients had to consume two capsules a day as per approved dosage is primarily used to treat prostate cancer patients.
The objective behind the launch of Enzalutamide 160 mg is to ensure better efficacy, minimum side effects, contain relapse cases by blocking the hormones of cancer cells providing an evolved treatment.
Raheel Shah, Director Business Development from BDR Pharmaceuticals Int’l, Mumbai said, “Our focussed launch of such expanded brand strength will add value to Indian Oncology patients as well as provide an opportunity for Medical Physicians to comply with patient outcome and standard treatment protocol. This represents a firm commitment to providing access to affordable medicines for Indian cancer patients with high a quality standard”.
Given the strength of BDR Pharma’s Oncology portfolio, another first-time launch of Enzalutamide 160mg in its basket was awaited by many Indian oncologists for the patient’s convenience. A patient will now have to consume only one capsule a day making it patient compliant, thereby reducing the associated stress of an already stressed cancer patient.
